Targeted therapy in nuclear medicine - Current status and future prospects

W. J G Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, B. Brans

Research output: Contribution to journalArticle

Abstract

In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal antibodies (mAbs), the developments in the application of radiolabeled small receptor-specific molecules such as meta-iodobenzylguanidine and peptides and the position of locoregional treatment in malignant involvement of the liver are reviewed. The introduction of recombinant human thyroid-stimulating hormone and the possibility to enhance iodine uptake with retinoids has changed the radioiodine treatment protocol of patients with thyroid cancer. Introduction of radiolabeled mAbs has provided additional treatment options in patients with malignant lymphoma, while a similar approach proves to be cumbersome in patients with solid tumors. With radiolabeled small molecules that target specific receptors on tumor cells, high radiation doses can be directed to tumors in patients with disseminated disease. Radiolabeled somatostatin derivatives for the treatment of neuroendocrine tumors are the role model for this approach. Locoregional treatment with radiopharmaceuticals of patients with hepatocellular carcinoma or metastases to the liver may be used in inoperable cases, but may also be of benefit in a neo-adjuvant or adjuvant setting. Significant developments in the application of targeted radionuclide therapy have taken place. New treatment modalities have been introduced in the clinic. The concept of combining therapeutic radiopharmaceuticals with other treatment modalities is more extensively explored.

Original languageEnglish
Pages (from-to)1782-1792
Number of pages11
JournalAnnals of Oncology
Volume18
Issue number11
DOIs
Publication statusPublished - Nov 2007

Fingerprint

Nuclear Medicine
Therapeutics
Radiopharmaceuticals
Thyroid Neoplasms
Lymphoma
Neoplasms
Monoclonal Antibodies
3-Iodobenzylguanidine
Neuroendocrine Tumors
Liver
Retinoids
Thyrotropin
Clinical Protocols
Somatostatin
Radioisotopes
Iodine
Hepatocellular Carcinoma
Radiation
Neoplasm Metastasis
Peptides

Keywords

  • Peptide receptor radionuclide therapy
  • Radio immunotherapy
  • Radioiodine therapy
  • Radionuclide therapy
  • Radiopharmaceuticals
  • Transarterial radionuclide therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oyen, W. J. G., Bodei, L., Giammarile, F., Maecke, H. R., Tennvall, J., Luster, M., & Brans, B. (2007). Targeted therapy in nuclear medicine - Current status and future prospects. Annals of Oncology, 18(11), 1782-1792. https://doi.org/10.1093/annonc/mdm111

Targeted therapy in nuclear medicine - Current status and future prospects. / Oyen, W. J G; Bodei, L.; Giammarile, F.; Maecke, H. R.; Tennvall, J.; Luster, M.; Brans, B.

In: Annals of Oncology, Vol. 18, No. 11, 11.2007, p. 1782-1792.

Research output: Contribution to journalArticle

Oyen, WJG, Bodei, L, Giammarile, F, Maecke, HR, Tennvall, J, Luster, M & Brans, B 2007, 'Targeted therapy in nuclear medicine - Current status and future prospects', Annals of Oncology, vol. 18, no. 11, pp. 1782-1792. https://doi.org/10.1093/annonc/mdm111
Oyen WJG, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M et al. Targeted therapy in nuclear medicine - Current status and future prospects. Annals of Oncology. 2007 Nov;18(11):1782-1792. https://doi.org/10.1093/annonc/mdm111
Oyen, W. J G ; Bodei, L. ; Giammarile, F. ; Maecke, H. R. ; Tennvall, J. ; Luster, M. ; Brans, B. / Targeted therapy in nuclear medicine - Current status and future prospects. In: Annals of Oncology. 2007 ; Vol. 18, No. 11. pp. 1782-1792.
@article{4bfb4e4c577d4a94be14c741165420df,
title = "Targeted therapy in nuclear medicine - Current status and future prospects",
abstract = "In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal antibodies (mAbs), the developments in the application of radiolabeled small receptor-specific molecules such as meta-iodobenzylguanidine and peptides and the position of locoregional treatment in malignant involvement of the liver are reviewed. The introduction of recombinant human thyroid-stimulating hormone and the possibility to enhance iodine uptake with retinoids has changed the radioiodine treatment protocol of patients with thyroid cancer. Introduction of radiolabeled mAbs has provided additional treatment options in patients with malignant lymphoma, while a similar approach proves to be cumbersome in patients with solid tumors. With radiolabeled small molecules that target specific receptors on tumor cells, high radiation doses can be directed to tumors in patients with disseminated disease. Radiolabeled somatostatin derivatives for the treatment of neuroendocrine tumors are the role model for this approach. Locoregional treatment with radiopharmaceuticals of patients with hepatocellular carcinoma or metastases to the liver may be used in inoperable cases, but may also be of benefit in a neo-adjuvant or adjuvant setting. Significant developments in the application of targeted radionuclide therapy have taken place. New treatment modalities have been introduced in the clinic. The concept of combining therapeutic radiopharmaceuticals with other treatment modalities is more extensively explored.",
keywords = "Peptide receptor radionuclide therapy, Radio immunotherapy, Radioiodine therapy, Radionuclide therapy, Radiopharmaceuticals, Transarterial radionuclide therapy",
author = "Oyen, {W. J G} and L. Bodei and F. Giammarile and Maecke, {H. R.} and J. Tennvall and M. Luster and B. Brans",
year = "2007",
month = "11",
doi = "10.1093/annonc/mdm111",
language = "English",
volume = "18",
pages = "1782--1792",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "11",

}

TY - JOUR

T1 - Targeted therapy in nuclear medicine - Current status and future prospects

AU - Oyen, W. J G

AU - Bodei, L.

AU - Giammarile, F.

AU - Maecke, H. R.

AU - Tennvall, J.

AU - Luster, M.

AU - Brans, B.

PY - 2007/11

Y1 - 2007/11

N2 - In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal antibodies (mAbs), the developments in the application of radiolabeled small receptor-specific molecules such as meta-iodobenzylguanidine and peptides and the position of locoregional treatment in malignant involvement of the liver are reviewed. The introduction of recombinant human thyroid-stimulating hormone and the possibility to enhance iodine uptake with retinoids has changed the radioiodine treatment protocol of patients with thyroid cancer. Introduction of radiolabeled mAbs has provided additional treatment options in patients with malignant lymphoma, while a similar approach proves to be cumbersome in patients with solid tumors. With radiolabeled small molecules that target specific receptors on tumor cells, high radiation doses can be directed to tumors in patients with disseminated disease. Radiolabeled somatostatin derivatives for the treatment of neuroendocrine tumors are the role model for this approach. Locoregional treatment with radiopharmaceuticals of patients with hepatocellular carcinoma or metastases to the liver may be used in inoperable cases, but may also be of benefit in a neo-adjuvant or adjuvant setting. Significant developments in the application of targeted radionuclide therapy have taken place. New treatment modalities have been introduced in the clinic. The concept of combining therapeutic radiopharmaceuticals with other treatment modalities is more extensively explored.

AB - In recent years, a number of new developments in targeted therapies using radiolabeled compounds have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of lymphoma and solid tumors with radiolabeled monoclonal antibodies (mAbs), the developments in the application of radiolabeled small receptor-specific molecules such as meta-iodobenzylguanidine and peptides and the position of locoregional treatment in malignant involvement of the liver are reviewed. The introduction of recombinant human thyroid-stimulating hormone and the possibility to enhance iodine uptake with retinoids has changed the radioiodine treatment protocol of patients with thyroid cancer. Introduction of radiolabeled mAbs has provided additional treatment options in patients with malignant lymphoma, while a similar approach proves to be cumbersome in patients with solid tumors. With radiolabeled small molecules that target specific receptors on tumor cells, high radiation doses can be directed to tumors in patients with disseminated disease. Radiolabeled somatostatin derivatives for the treatment of neuroendocrine tumors are the role model for this approach. Locoregional treatment with radiopharmaceuticals of patients with hepatocellular carcinoma or metastases to the liver may be used in inoperable cases, but may also be of benefit in a neo-adjuvant or adjuvant setting. Significant developments in the application of targeted radionuclide therapy have taken place. New treatment modalities have been introduced in the clinic. The concept of combining therapeutic radiopharmaceuticals with other treatment modalities is more extensively explored.

KW - Peptide receptor radionuclide therapy

KW - Radio immunotherapy

KW - Radioiodine therapy

KW - Radionuclide therapy

KW - Radiopharmaceuticals

KW - Transarterial radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=36148946792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148946792&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm111

DO - 10.1093/annonc/mdm111

M3 - Article

C2 - 17434893

AN - SCOPUS:36148946792

VL - 18

SP - 1782

EP - 1792

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -